MedTrace Logo

The Pharmacokinetics and Pharmacodynamics of Hemp-based Topical Cannabinoid Products

NCT04741477 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2023-03-10

No results posted yet for this study

Summary

This study will evaluate the pharmacokinetic and pharmacodynamic effects of hemp-based Cannabidiol (CBD) topical products (e.g., lotions, creams, patches) that contain low levels of delta-9-tetrahydrocannabinol (THC).

Conditions

  • Cannabis
  • Drug Effect

Interventions

DRUG

CBD

CBD will be topically applied

DRUG

THC

THC will be topically applied

DRUG

Placebo

a placebo product (without cannabinoids) will be topically applied

Sponsors & Collaborators

  • Substance Abuse and Mental Health Services Administration (SAMHSA)

    collaborator FED

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Tory Spindle, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-14
Primary Completion
2022-09-16
Completion
2022-09-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04741477 on ClinicalTrials.gov